Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation

Part of paid clinical trials in Atlanta, Georgia.

Sponsor
Northside Hospital, Inc.
Study ID
NCT05417971
Status
Recruiting
Apply to this trial

Conditions

  • Hematologic Malignancy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Fludarabine — OTHER
    Reduced-intensity fludarabine with intermediate-dose TBI

Study Details

This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source.

Key Dates

Start date
Aug 29, 2022
Status verified
Apr 2026
Primary completion
Jul 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
20 participants (estimated)

Primary Outcome Measure

Compare the time to recovery of circulating neutrophils and platelets of all patients to determine incidence of graft rejection [ Time Frame: 30 days after transplant ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Caitlin GuzowskiAtlantaGeorgia30342
Caitlin Guzowski, MBA, MHA
[email protected]
404-851-8523
H. Kent Holland, MD (SUB_INVESTIGATOR)
Asad Bashey, MD (SUB_INVESTIGATOR)
Lawrence E Morris, MD (SUB_INVESTIGATOR)
Scott Solomon, MD (SUB_INVESTIGATOR)
Melhem Solh, MD (PRINCIPAL_INVESTIGATOR)
Lizamarie Bachier-Rodriguez, MD (SUB_INVESTIGATOR)

Find similar trials in Atlanta, GA

By research site
Caitlin Guzowski· Atlanta, GA

Related Studies